Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
WWLP Springfield on MSN5d
New Bedford man sentenced to prison for stealing veteran’s disability benefitsA New Bedford man was sentenced to prison in federal court on Friday for stealing over $450,000 in disability benefits that ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
GlobalData on MSN3d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatmentThe US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...
DNL343 showed no significant difference in ALSFRS-R scores or secondary endpoints compared to placebo over 24 weeks. Analysts await late-2025 data on biomarkers and subgroup findings for DNL343 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback